AI assistant
Quantum Biopharma Ltd. — Interim / Quarterly Report 2022
Aug 12, 2022
34475_ffr_2022-08-12_68631253-fa27-40af-ba27-7acd0508485a.zip
Interim / Quarterly Report
Open in viewerOpens in your device viewer
6-K 1 form6k.htm FORM 6-K FSD Pharma Inc.: Form 6-K - Filed by newsfilecorp.com
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549
FORM 6-K
REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934
For the month of August 2022
Commission File Number: 001-39152
FSD PHARMA INC. (Translation of registrant's name into English)
199 Bay St., Suite 4000 Toronto, Ontario M5L 1A9, Canada (Address of principal executive offices)
Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F. Form 20-F [ ] Form 40-F [ X ]
Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1):
Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7):
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
| FSD Pharma Inc. | |
|---|---|
| (Registrant) | |
| Date: August 5, 2022 | By: /s/ Nathan Coyle |
| Name: Nathan Coyle | |
| Title: Chief Financial Officer |
EXHIBIT INDEX
| Exhibit | Description |
|---|---|
| 99.1 | Condensed Consolidated Interim Financial Statements for the period ended June 30, 2022 |
| 99.2 | Management’s Discussion and Analysis for the period ended June 30, 2022 |
| 99.3 | Form 52-109F2 Certification of Interim Filings - CEO |
| 99.4 | Form 52-109F2 Certification of Interim Filings - CFO |